Overview
Acromegaly is a rare hormonal disorder most often caused by a growth hormone–secreting pituitary adenoma, also called a somatotroph adenoma. In more than 95% of cases, the tumor arises in the pituitary gland at the base of the brain. Over time, excess growth hormone leads to elevated insulin-like growth factor 1 (IGF-1), which drives the characteristic features of acromegaly, including enlarged hands and feet, facial changes, joint pain, sweating, sleep apnea, and metabolic complications such as diabetes and hypertension.
Although the diagnosis of acromegaly is confirmed through biochemical testing, imaging is essential for locating the tumor, estimating its size and extent, and planning treatment. High-quality pituitary imaging has become one of the most important factors in determining both the accuracy of diagnosis and the likelihood of long-term disease control.
Why Imaging Matters
The main treatment options for acromegaly are pituitary surgery, medical therapy, and radiotherapy. Surgery is usually the first-line treatment when the tumor can be removed safely, especially if the adenoma is well defined and not extensively invading nearby structures. Radiotherapy may be considered when surgery cannot fully control the disease or when medication is insufficient.
However, these treatments are not without risk. The pituitary gland also produces hormones needed for normal body function, including thyroid-stimulating hormone, ACTH, gonadotropins, and prolactin. Surgery or radiation can damage the remaining healthy gland and cause hypopituitarism, requiring lifelong hormone replacement. The risk is higher when treatment is repeated or performed in centers without specialized expertise.
For this reason, accurate imaging is not just a diagnostic step; it is central to choosing the safest and most effective therapy. Imaging helps identify whether disease is newly diagnosed, residual after surgery, or recurrent after earlier treatment.
Typical Imaging Findings in Acromegaly
Most somatotroph adenomas are macroadenomas, meaning they are larger than 10 mm. Around 70% of tumors fall into this category. Larger tumors may extend into the cavernous sinus, compress the optic chiasm, or erode surrounding structures, all of which affect surgical planning and prognosis.
At the same time, improved access to brain imaging has led to earlier detection of smaller pituitary lesions, including microadenomas. These smaller tumors can be harder to see and localize, particularly if they are only a few millimeters in size or if prior surgery has altered the anatomy. This creates new challenges for radiologists and endocrinologists, who must distinguish true tumor tissue from post-treatment change, normal gland tissue, or incidental findings.
Preferred Imaging Technique
Magnetic resonance imaging, or MRI, is the preferred imaging test for suspected or confirmed acromegaly. A dedicated pituitary MRI protocol is essential. In most cases, this includes thin-section, high-resolution T1-weighted images before and after gadolinium contrast, often with dynamic contrast-enhanced sequences to improve the detection of small adenomas.
Dynamic MRI can be especially helpful because pituitary adenomas often enhance differently from normal pituitary tissue during the first moments after contrast injection. This contrast difference can reveal a lesion that would otherwise be missed. High-field MRI, such as 3 Tesla scanners, may further improve visualization in experienced centers.
Computed tomography, or CT, is less sensitive for pituitary soft tissue but may be useful when MRI is contraindicated or when bony anatomy needs to be assessed. For example, CT can help show sellar erosion or calcification, although these are not the main features of somatotroph adenomas.
Challenges in Imaging Diagnosis
Despite the importance of imaging, there is still no universal agreement on the ideal scanning protocol for acromegaly. Current practice is highly variable across centers, which makes it harder to compare outcomes and can delay optimal care.
Several factors contribute to this inconsistency:
1. Different MRI magnet strengths and slice thicknesses
2. Variation in the use of dynamic contrast imaging
3. Differences in radiologist experience with pituitary tumors
4. Limited access to specialized pituitary centers
5. Difficulty interpreting scans after surgery or radiotherapy
These issues are particularly relevant when the tumor is small, invasive, or recurrent. In such cases, a standard brain MRI may be insufficient, and a specialized pituitary protocol is needed.
Functional and Molecular Imaging
In difficult cases, conventional MRI may not clearly show the lesion responsible for hormone excess. Functional imaging and molecular imaging techniques can add value by identifying biologically active tissue rather than relying only on anatomy.
Examples include PET-based approaches using different tracers, which are being studied to help localize pituitary tumors or assess tumor behavior. These methods are not yet routine for all patients, but they may be useful in specialized centers, especially when MRI findings are equivocal, when postoperative anatomy is complex, or when recurrent disease is suspected.
These newer techniques may eventually help determine which tumors are more aggressive, which patients are most likely to respond to medical therapy, and which lesions are best targeted by surgery or radiotherapy.
A Tiered Imaging Approach
Based on the current evidence, a practical tiered approach to imaging is recommended.
First, all patients with suspected acromegaly should undergo biochemical confirmation with IGF-1 measurement and, when needed, oral glucose suppression testing for growth hormone. Once the diagnosis is established, dedicated pituitary MRI should be performed.
Second, if MRI shows a clear adenoma, imaging findings should be integrated with clinical and hormonal data to guide treatment. Tumor size, invasion, and relation to critical structures such as the optic nerves and cavernous sinus should be described in detail.
Third, if MRI is negative or uncertain but biochemical evidence strongly supports acromegaly, referral to an experienced pituitary center is recommended. Additional imaging, repeat MRI with optimized protocols, or advanced molecular imaging may be considered.
Fourth, after surgery or radiotherapy, follow-up imaging should be tailored to the patient’s clinical course. Residual lesions, recurrence, and treatment-related changes must be carefully distinguished, often over serial scans rather than a single examination.
This structured approach reduces uncertainty and supports individualized treatment planning.
Impact on Treatment Outcomes
The quality of pituitary imaging has direct consequences for treatment outcomes. When the tumor is accurately localized, surgeons can plan a more focused operation, increasing the chance of complete resection while minimizing harm to normal pituitary tissue. When imaging identifies invasive disease, clinicians can anticipate the need for adjuvant medical therapy or radiotherapy rather than relying on surgery alone.
Good imaging also improves patient counseling. Individuals can be told more realistically whether cure is likely, whether long-term medication may be needed, and what risks are associated with repeated interventions.
In contrast, poor imaging can lead to incomplete surgery, unnecessary repeat procedures, or delayed diagnosis of residual disease. These outcomes can increase the burden of treatment and worsen quality of life.
Why Specialized Centers Matter
Acromegaly care is best delivered in centers with expertise in pituitary disease. Such centers typically have endocrinologists, neurosurgeons, neuroradiologists, radiation oncologists, and pituitary nurses working together. This multidisciplinary model improves interpretation of complex imaging findings and helps align the imaging strategy with the intended treatment.
A Pituitary Tumor Center of Excellence is especially valuable for patients with recurrent disease, inconclusive scans, invasive tumors, or prior failed surgery. In these settings, imaging protocols are more standardized, and advanced methods are more readily available.
Practical Takeaways for Clinicians and Patients
For clinicians, the key message is that imaging in acromegaly should never be treated as a routine afterthought. It is a core part of diagnosis, surgical planning, and follow-up. The scan should be tailored to the clinical question, preferably using a dedicated pituitary MRI protocol interpreted by an experienced specialist.
For patients, it is important to understand that imaging helps determine not only where the tumor is, but also what treatment is safest and most likely to work. A clear scan can support surgery, while an unclear scan may require referral for expert review or additional testing.
Conclusion
Pituitary adenoma imaging plays a decisive role in the diagnosis and management of acromegaly. Because most cases are caused by a somatotroph adenoma, high-resolution pituitary MRI is central to locating the tumor and guiding therapy. As imaging technology advances and smaller lesions are detected earlier, standardized protocols and expert interpretation are becoming increasingly important.
The best outcomes are achieved when imaging is integrated with endocrine testing, multidisciplinary decision-making, and treatment in specialized pituitary centers. A tiered, patient-specific imaging strategy can improve diagnostic confidence, reduce treatment-related harm, and support better long-term control of acromegaly.
